Healthcare -
Biotechnology - NASDAQ - BM
$ 26.81
-3.02 %
$ 1.96 B
Market Cap
-112.25
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
Kiniksa Pharmaceuticals, Ltd.
| Revenue | 423 M |
| Cost Of Revenue | 60.9 M |
| Gross Profit | 362 M |
| Operating Expenses | 408 M |
| Operating Income | -45.6 M |
| Other Expenses | -2.42 M |
| Net Income | -43.2 M |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Revenue | 423.2 | 270.3 | 220.2 | 38.5 | 0 | 0 | 0 | 0 | 0 |
| GROSS PROFIT | |||||||||
| Cost Of Revenue | 60.9 | 56.5 | 47.0 | 9.1 | 3.8 | 3.3 | 0.3 | 28 K | 22 K |
| Gross Profit | 362.3 | 213.7 | 173.2 | 29.4 | (3.8) | (3.3) | (0.3) | 28 K | 22 K |
| OPERATING INCOME | |||||||||
| Operating Expenses | 407.9 | 238.9 | 163.4 | 186.1 | 157.4 | 170.0 | 108.2 | 65.4 | 24.0 |
| Selling, General and Administrative Expenses | 168.0 | 129.4 | 98.0 | 85.9 | 45.3 | 35.0 | 21.6 | 9.0 | 6.6 |
| Research and Development Expenses | 111.6 | 76.1 | 65.5 | 99.3 | 112.0 | 135.0 | 86.6 | 56.4 | 17.4 |
| Operating Income | (45.6) | (25.2) | 7.4 | (156.6) | (157.4) | (170.0) | (108.2) | (65.4) | (24.0) |
| PRE-TAX INCOME | |||||||||
| Interest Income Expense | 0 | 0 | 1.3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income | 9.5 | 8.5 | 1.3 | 97 K | 1.1 | 6.0 | 4.7 | 0.5 | 65 K |
| Pre-Tax Income | (36.2) | (16.7) | 11.0 | (156.5) | (156.2) | (163.9) | (103.4) | (64.9) | (23.9) |
| NET INCOME | |||||||||
| Tax Provision | 7.0 | (30.7) | (172.3) | 1.4 | 5.2 | (2.0) | (0.2) | 2 K | 36 K |
| Net Income | (43.2) | 14.1 | 183.4 | (157.9) | (161.4) | (161.9) | (103.2) | (64.9) | (24.0) |
| EPS | 0.6 | 0.2 | 2.64 | 2.3 | 2.61 | 2.99 | 3.49 | 2 | 0.74 |